RWC Asset Management LLP Buys 342 Shares of Hologic, Inc. (NASDAQ:HOLX)

RWC Asset Management LLP boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 13.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,971 shares of the medical equipment provider’s stock after acquiring an additional 342 shares during the quarter. RWC Asset Management LLP’s holdings in Hologic were worth $214,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Covestor Ltd lifted its stake in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. Brooklyn Investment Group boosted its holdings in Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the period. Empirical Finance LLC grew its position in Hologic by 1.8% during the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares during the last quarter. Finally, Trivant Custom Portfolio Group LLC grew its position in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after acquiring an additional 169 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $64.47 on Monday. The business’s fifty day moving average price is $69.91 and its 200 day moving average price is $76.53. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The company has a market capitalization of $14.47 billion, a PE ratio of 20.34, a P/E/G ratio of 2.14 and a beta of 0.98. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HOLX. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, UBS Group upped their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.